Theralase Technologies (Theralase Technologies) EV-to-EBIT : -11.30 (As of May. 04, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Theralase Technologies's Enterprise Value is $28.26 Mil. Theralase Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.50 Mil. Therefore, Theralase Technologies's EV-to-EBIT for today is -11.30.

The historical rank and industry rank for Theralase Technologies's EV-to-EBIT or its related term are showing as below:

TLTFF' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.38 Med: -8.83 Max: -1.49
Current: -11.25

During the past 13 years, the highest EV-to-EBIT of Theralase Technologies was -1.49. The lowest was -28.38. And the median was -8.83.

TLTFF's EV-to-EBIT is ranked worse than
100% of 460 companies
in the Medical Devices & Instruments industry
Industry Median: 20.215 vs TLTFF: -11.25

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Theralase Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was $31.33 Mil. Theralase Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.50 Mil. Theralase Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -7.99%.

Theralase Technologies EV-to-EBIT Historical Data

The historical data trend for Theralase Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies EV-to-EBIT Chart

Theralase Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-7.80

-5.55

-16.56

-13.09

-8.88

Theralase Technologies Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-10.00	-13.09	-11.91	-15.69	-8.88

Competitive Comparison of Theralase Technologies's EV-to-EBIT

For the Medical Devices subindustry, Theralase Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's EV-to-EBIT falls into.

Theralase Technologies EV-to-EBIT Calculation

Theralase Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	28.264	/	-2.502
	=	-11.30

Theralase Technologies's current Enterprise Value is $28.26 Mil.
Theralase Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.50 Mil.

Theralase Technologies (OTCPK:TLTFF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Theralase Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-2.502	/	31.325696
	=	-7.99 %

Theralase Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was $31.33 Mil.
Theralase Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.50 Mil.

Theralase Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies (Theralase Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.